https://ymaho.com/breakthrough-in-glioblastoma-treatment-neovax-vaccine-improves-survival-asco-2026
Dana-Farber's personalized vaccine NeoVax showed median survival of 36.9 months in glioblastoma at ASCO 2026. Learn how immunotherapy works and who it suits.